Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Equity Average (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Equity Average for 8 consecutive years, with $358.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Equity Average fell 35.35% year-over-year to $358.8 million, compared with a TTM value of $358.8 million through Jun 2025, down 35.35%, and an annual FY2024 reading of $269.4 million, up 31.37% over the prior year.
  • Equity Average was $358.8 million for Q2 2025 at Autolus Therapeutics, down from $399.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $554.9 million in Q2 2024 and bottomed at $146.0 million in Q4 2023.
  • Average Equity Average over 5 years is $314.0 million, with a median of $282.8 million recorded in 2023.
  • The sharpest move saw Equity Average tumbled 36.5% in 2023, then skyrocketed 209.7% in 2024.
  • Year by year, Equity Average stood at $261.7 million in 2021, then fell by 12.14% to $229.9 million in 2022, then crashed by 36.5% to $146.0 million in 2023, then surged by 209.7% to $452.1 million in 2024, then dropped by 20.65% to $358.8 million in 2025.
  • Business Quant data shows Equity Average for AUTL at $358.8 million in Q2 2025, $399.2 million in Q1 2025, and $452.1 million in Q4 2024.